BillionToOne (BLLN) Price to Sales (2025 - 2026)

BillionToOne's (BLLN) quarterly Price to Sales came in at 51.33 in Q2 2026, up 53.29% quarter-over-quarter from 33.49 in Q1 2026.

Analysis

BillionToOne (BLLN) Price to Sales (2025 - 2026) Analysis & Trends

BillionToOne has disclosed Price to Sales across 2 years of filings, most recently posting 51.33 for Q2 2026.

In Q2 2026, Price to Sales changed N/A year-over-year to 51.33; the TTM figure through Jun 2026 stood at 14.14 (changed N/A YoY), while the FY2025 annual figure was 12.29, changed N/A from the prior year.
Price to Sales came in at 51.33 for Q2 2026 at BillionToOne, up from 33.49 in the prior quarter.
In the past five years, Price to Sales ranged from a high of 51.33 in Q2 2026 to a low of 33.49 in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Natera	47.13 Bn	46.03 Bn	486.15 Mn
2	Labcorp Holdings	26.44 Bn	26.32 Bn	1.11 Bn
3	Quest Diagnostics	26.16 Bn	25.84 Bn	1.03 Bn
4	Guardant Health	21.57 Bn	20.51 Bn	219.03 Mn
5	Tempus AI	11.32 Bn	10.51 Bn	274.25 Mn
6	Caris Life Sciences	7.08 Bn	6.29 Bn	182.38 Mn
7	Sotera Health	5.39 Bn	5.04 Bn	177.96 Mn
8	BillionToOne	4.65 Bn	4.11 Bn	77.11 Mn
9	iRhythm Holdings	4.05 Bn	3.46 Bn	163.21 Mn
10	Adaptive Biotechnologies	3.86 Bn	3.53 Bn	51.39 Mn

Historic Data

Download Data